Row over Mylan EpiPen boils down to plastic cap
Firm urges FDA to approve Teva's generic devices only if they were truly equivalent and wouldn't confuse patients
Washington
THE lack of a cheaper version of Mylan NV's EpiPen shot may come down to a dispute between drugmakers over a plastic cap.
Unlike Mylan's one-cap EpiPen, Teva Pharmaceutical Industries' proposed substitutable generic version has two caps, including a removable one that covers the spot where its needle extends. In a petition to the US Food and Drug Administration (FDA), Mylan cited that difference as the key reason the agency should reject Teva's generic - which is exactly what happened in February of this year.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director
GSK profit drops 23% in Q1 on higher costs
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices